Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Prospective Phase II Study Evaluating the Efficacy and Safety of PD-1 Inhibitors Maintenance in Patients With Refractory/Relapsed Classical Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation

NCT06812858 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT06812858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Prospective Phase II Study Evaluating the Efficacy and Safety of PD-1 Inhibitors Maintenance in Patients With Refractory/Relapsed Classical Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
January 9, 2024
Completion date
September 30, 2030
Enrollment
83 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma